Press release
Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge
DelveInsight's, "Multiple sclerosis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Find out more about Multiple Sclerosis treatment drugs @ Drugs for Multiple Sclerosis Treatment [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from Multiple Sclerosis Pipeline Report
* August 2024:- Hoffmann-La Roche- A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials. This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).
* August 2024:- Novartis Pharmaceuticals- Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS. This study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS patients
* DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Multiple Sclerosis treatment.
* The leading Multiple Sclerosis Companies working in the market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
* Promising Multiple Sclerosis Therapies in the various stages of development include 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others
Request a sample and discover the recent advances in Multiple Sclerosis treatment drugs @ Multiple Sclerosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Multiple Sclerosis Emerging Drugs Profile
* Ublituximab: TG Therapeutics
* IMU-838: Immunic
* ATA188: Atara Biotherapeutics
* ANK-700: ANOKION
Multiple Sclerosis Therapeutics Assessment
There are approx. 100+ key Multiple Sclerosis companies which are developing the therapies for Multiple sclerosis. The Multiple Sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.
DelveInsight's Multiple Sclerosis pipeline report covers around 100+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Learn more about the emerging Multiple Sclerosis pipeline therapies @ Multiple Sclerosis Clinical Trials [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Multiple Sclerosis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Multiple Sclerosis Companies
TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others
Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, visit @ Multiple Sclerosis Drugs [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Multiple Sclerosis Pipeline Report
* Coverage- Global
* Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others
* Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others
For further information on the Multiple Sclerosis Pipeline Therapeutics, reach out @ Multiple Sclerosis Treatment Drugs [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Multiple sclerosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Multiple sclerosis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Ublituximab: TG Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EHP 101: Emerald Health Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ASLAN 003: ASLAN Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Lucid MS: FSD Pharma
* Drug profiles in the detailed report.....
* Inactive Products
* Multiple sclerosis Key Companies
* Multiple sclerosis Key Products
* Multiple sclerosis- Unmet Needs
* Multiple sclerosis- Market Drivers and Barriers
* Multiple sclerosis- Future Perspectives and Conclusion
* Multiple sclerosis Analyst Views
* Multiple sclerosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-sclerosis-pipeline-drugs-2024-tg-therapeutics-immunic-atara-biotherapeutics-anokion-imstem-biotechnology-merck-serono-cinnagen-immune-response-biopharma-inc-clene-nanomedicine-ge]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Sclerosis Pipeline Drugs 2024 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, Ge here
News-ID: 3620170 • Views: …
More Releases from ABNewswire

Counselling Birmingham UK: How to Find Effective Support Close to Home
When life feels overwhelming, talking to someone trained to listen and guide can make a world of difference. For many people, the first step towards change begins with searching for counselling Birmingham UK [https://www.google.com/maps/place/counselling+Birmingham+UK/@52.4723762,-1.9238507,17z/data=!3m1!4b1!4m6!3m5!1s0x4870bd9ee5af19cb:0x760273ced5d9fbd8!8m2!3d52.4723762!4d-1.9238507!16s%2Fg%2F11spn9vsdq?hl=en-GB&entry=ttu&g_ep=EgoyMDI1MDkyNC4wIKXMDSoASAFQAw%3D%3D] or looking up counselling near me. This search is more than just finding a name on a list; it's about finding the right support, the right approach, and the right connection to help you move forward.
Understanding…

Brokrloans Highlights the Shift from Banks to Brokers in Today's Housing Market
More than 60% of Australian home loans now come through brokers, and this number keeps growing year after year. That's not surprising at all.
A mortgage broker can help you save time, effort, and money while you're buying property. These professionals have connections with numerous lenders, including banks, credit unions, and alternative lending sources. This gives you substantially more choices than going straight to a single bank. Additionally, brokers work with…

FPLawyers Safeguarding Families with Expert Wills and Estates Legal Services
Have you ever wondered what will happen to your belongings after you die? Estate planning is not just for the rich, it is an essential way to secure the future of your family.The law will decide where your estate goes if you die without a will. This might not match what you actually wanted.
A legally valid will needs more than just writing down your priorities. Your will must be in…

GorillaCreative Unveils Innovative Training Video Formats to Boost Corporate Per …
According to credible studies, nearly 66% of people consume training videos at least once a week, and many users prefer videos over articles or documents for learning. In this context, your employees can also learn more efficiently when they see things in action. Reading materials may not register with them as much. Therefore, you can start investing in training videos to strengthen your company's learning strategy. Interestingly, these videos can…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…